Skip to main content
WTG
NASDAQ Life Sciences

KIKA Merger Proxy Reveals 1,567% Revenue Surge and 66% Customer Concentration

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$10.56
Mkt Cap
$18.043M
52W Low
$9.74
52W High
$10.62
52W Position info
8.4% above low
Off High info
at 52W high
Rel. Volume
Market data snapshot near publication time

WTG is trading near its 52-week low of $9.74 (8.4% above the low).

Summary

Wintergreen's latest S-4 amendment reveals KIKA's FY2026 revenue surged to $21.84M but with 66% customer concentration and 9% retention, plus a new sponsor note extending the merger deadline to September 30, 2026.


Key Events · M&A and Partnerships · WTG

  • KIKA FY2026 Revenue Surges 1,567%

    Audited financials show KIKA revenue jumped from $1.31M in FY2025 to $21.84M in FY2026, with net income of $683,578 versus a prior-year loss of $172,819.

  • 66% Revenue Concentration in Four Clients

    Four key clients generated 66% of FY2026 revenue, while customer retention rate fell to 9% from 29% — a fragile growth profile.

  • New $184,635 Sponsor Note Extends Deadline

    A non-interest-bearing promissory note issued September 1, 2026 funds a one-month extension of the business combination deadline to September 30, 2026, convertible into units at $10.00.

  • Minimum Cash Condition at Risk

    Pro forma analysis shows redemptions exceeding 93.28% would drop net tangible assets below the $5,000,001 minimum cash condition, potentially terminating the merger.


Analysis · WTG · Life Sciences

This sixth S-4 amendment adds audited FY2026 financials showing KIKA's revenue exploded from $1.31M to $21.84M, but the growth is highly concentrated — four clients account for 66% of revenue and customer retention collapsed to 9%. The filing also discloses a new $184,635 sponsor note to extend the merger deadline to September 30, 2026, and warns that redemptions above 93.28% would breach the $5M minimum cash condition. For a SPAC trading near its 52-week high, the combination of explosive but fragile revenue growth and a tight cash condition makes this a critical update for shareholders deciding whether to redeem or hold through the merger.

How filings like this one have moved

In the 30 days to Sep 11, 2026, 30.2% of the 1961 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, WTG was trading at $10.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18M. The 52-week trading range was $9.74 to $10.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

WTG - Latest Insights

WTG
Aug 14, 2026, 9:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.48
Real-time Price: $10.56 info
Change: Low Volume info
Market Cap: $18.043M info
WTG
Jul 02, 2026, 1:49 PM EDT
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $10.45
Real-time Price: $10.56 info
Change: Low Volume info
Market Cap: $18.043M info
WTG
May 14, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.30
Real-time Price: $10.56 info
Change: Low Volume info
Market Cap: $18.043M info
WTG
Apr 17, 2026, 6:35 AM EDT
Filing Type: S-4
Importance Score:
9
Price at Filing: $10.30
Real-time Price: $10.56 info
Change: Low Volume info
Market Cap: $18.043M info
WTG
Feb 27, 2026, 9:00 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $10.24
Real-time Price: $10.56 info
Change: Low Volume info
Market Cap: $18.043M info